Kurt Saruhan Hülya, Toprak Murat
Turk J Phys Med Rehabil. 2020 May 18;66(2):147-153. doi: 10.5606/tftrd.2020.4068. eCollection 2020 Jun.
This study aims to evaluate pain-diminishing and quality of life-related outcomes of Kinesio taping in patients on non-steroidal anti-inflammatory drug (NSAID) therapy for post-thoracotomy pain syndrome (PTPS).
Between February 2016 and May 2017, a total 60 patients (39 males, 21 females; median age 43.5 years; range, 18 to 76 years) with PTPS were included in this single-center, prospective, randomized study. The patients were randomized into two groups based on five-day pain management protocol including NSAIDs per se (NSAID group; n=30) and NSAIDs plus Kinesio taping (NSAID-KT group; n=30) groups. Pain intensity (via visual pain scale [VAS]), neuropathic pain (Leeds Assessment of Neuropathic Symptoms and Signs [LANSS] Pain Scale), major chronic pain symptoms (via Short-Form McGill Pain Questionnaire [SF-MPQ-2]), and quality of life (via Nottingham Health Profile [NHP]) were assessed before and after five-day treatment period.
In both NSAID and NSAID-KT groups, treatment was associated with a significant decrease in the VAS-pain (p<0.001), LANSS Pain Scale scores (from median 8.0 to 3.0 and from median 18.5 to 15.0, respectively, p<0.001 for each), SF-MPQ scores (p<0.001), and physical mobility and pain domains of NHS (p<0.001 for each).
In conclusion, our study findings indicate no additional benefit of KT application on further amelioration of long-term PTPS in patients under NSAID analgesia. Both NSAID and NSAID-KT treatments produced a significant improvement in the VAS, LANSS, SF-MPQ scores, and in the quality of life after five-day treatment.
本研究旨在评估肌内效贴布对接受非甾体抗炎药(NSAID)治疗开胸术后疼痛综合征(PTPS)患者的疼痛减轻效果及生活质量相关结局。
在2016年2月至2017年5月期间,本单中心、前瞻性、随机研究纳入了总共60例PTPS患者(39例男性,21例女性;中位年龄43.5岁;范围18至76岁)。根据为期五天的疼痛管理方案,患者被随机分为两组,一组仅使用NSAIDs(NSAID组;n = 30),另一组使用NSAIDs加肌内效贴布(NSAID-KT组;n = 30)。在为期五天的治疗期前后,评估疼痛强度(通过视觉疼痛量表[VAS])、神经性疼痛(利兹神经病理性症状和体征评估[LANSS]疼痛量表)、主要慢性疼痛症状(通过简化麦吉尔疼痛问卷[SF-MPQ-2])以及生活质量(通过诺丁汉健康量表[NHP])。
在NSAID组和NSAID-KT组中,治疗均与VAS疼痛评分显著降低相关(p < 0.001),LANSS疼痛量表评分也显著降低(分别从中位值8.0降至3.0以及从中位值18.5降至15.0,每组p < 0.001),SF-MPQ评分降低(p < 0.001),以及NHS的身体活动能力和疼痛领域评分降低(每组p < 0.001)。
总之,我们的研究结果表明,在接受NSAID镇痛的患者中,应用肌内效贴布对进一步改善长期PTPS并无额外益处。NSAID治疗和NSAID-KT治疗在为期五天的治疗后,均使VAS、LANSS、SF-MPQ评分以及生活质量有显著改善。